Current and future approaches to antimycotic treatment in the era of resistant fungi and immunocompromised hosts
Authors:
- M SchallerMSM Schaller
- H.C KortingHKH.C Korting
- E.G.V EvansEEE.G.V Evans
- 1 February 2001
- journal article
- review article
- Published by Elsevier in International Journal of Antimicrobial Agents
- Vol. 17 (2) , 81-91
Abstract
No abstract availableKeywords
This publication has 92 references indexed in Scilit:
- Clinical, Cellular, and Molecular Factors That Contribute to Antifungal Drug ResistanceClinical Microbiology Reviews, 1998
- Candidiasis: Implications for Intensivists and PulmonologistsSeminars in Respiratory and Critical Care Medicine, 1997
- Cloning of Candida albicans genes conferring resistance to azole antifungal agents: characterization of CDR2, a new multidrug ABC transporter geneMicrobiology, 1997
- Resistance to fluconazole and cross‐resistance to amphotericin B in Candida albicans from AIDS patients caused by defective sterol Δ5,6‐desaturationFEBS Letters, 1997
- Amphotericin B: new life for an old drugTrends in Pharmacological Sciences, 1996
- Discovery and development of new systemic antifungalsTrends in Biotechnology, 1996
- Mechanisms of resistance to azole antifungal agents in Candida albicans isolates from AIDS patients involve specific multidrug transportersAntimicrobial Agents and Chemotherapy, 1995
- Mechanisms and clinical impact of antifungal drug resistanceMedical Mycology, 1994
- Fungal Burn Wound InfectionArchives of Surgery, 1991
- Structure and absolute configuration of the polyene macrolide antibiotic amphotericin BTetrahedron Letters, 1970